JPS62178520A - Metal-bonded active fibrous material containing marine algae - Google Patents
Metal-bonded active fibrous material containing marine algaeInfo
- Publication number
- JPS62178520A JPS62178520A JP61021055A JP2105586A JPS62178520A JP S62178520 A JPS62178520 A JP S62178520A JP 61021055 A JP61021055 A JP 61021055A JP 2105586 A JP2105586 A JP 2105586A JP S62178520 A JPS62178520 A JP S62178520A
- Authority
- JP
- Japan
- Prior art keywords
- algae
- magnesium
- calcium
- metal
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000195493 Cryptophyta Species 0.000 title abstract 5
- 239000002657 fibrous material Substances 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000011575 calcium Substances 0.000 claims abstract description 13
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 12
- 239000011777 magnesium Substances 0.000 claims abstract description 12
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 12
- 229910052742 iron Inorganic materials 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 241000199919 Phaeophyceae Species 0.000 claims abstract description 8
- 229910052751 metal Inorganic materials 0.000 claims abstract description 6
- 239000002184 metal Substances 0.000 claims abstract description 6
- 239000002253 acid Substances 0.000 claims abstract 4
- 239000007864 aqueous solution Substances 0.000 claims abstract 2
- 239000007787 solid Substances 0.000 claims 2
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229910001415 sodium ion Inorganic materials 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 206010020772 Hypertension Diseases 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 abstract description 3
- 229910001448 ferrous ion Inorganic materials 0.000 abstract description 3
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 abstract 3
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 229910001447 ferric ion Inorganic materials 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000835 fiber Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 241001474374 Blennius Species 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 241000512259 Ascophyllum nodosum Species 0.000 description 2
- 241001272567 Hominoidea Species 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- -1 iron ions Chemical class 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は海藻類、特に褐藻類、が本来有する血圧降下作
用、減塩作用等を一層改良する目的をもって、これにカ
ルシウム、マグネシウムあるいは鉄のイオン類を結合さ
せた健康ないしは栄養補給用食品組成物を提供すること
に関する。[Detailed Description of the Invention] [Field of Industrial Application] The present invention aims to further improve the antihypertensive and salt-reducing effects of seaweeds, particularly brown algae, by adding calcium, magnesium or iron to them. The present invention relates to providing a health or nutritional food composition in which ions are bound.
先に、本発明者は褐藻類を原料とし、これを無機酸等で
処理して脱金属した後にカリウム イオン溶液で処理し
て脱水、固体化した組成物を提供し、この組成物がす）
ＩＪウムの排泄量を減少させ、カリウムの排泄量を増
加させる効用があり、さらに脳文中による死亡数を低下
させる作用があることを動物（ラット）実験により実証
し、この組成物を活性繊維体すなわち［アクティブ フ
ァイバー略してＡＦＪと称して特許出願に及んだ（特願
昭５９−１５，８２１号及び特願昭６０−１２９゜０２
８号）。First, the present inventor provided a composition using brown algae as a raw material, which was treated with an inorganic acid etc. to demetalize it, and then treated with a potassium ion solution to dehydrate and solidify it.
Experiments on animals (rats) demonstrated that this composition has the effect of reducing the amount of IJum excreted and increasing the amount of potassium excreted, and also has the effect of reducing the number of deaths due to cerebral palsy. In other words, a patent application was filed under the name Active Fiber (AFJ) (Japanese Patent Application No. 59-15,821 and Japanese Patent Application No. 129-02-1982)
No. 8).
本発明は前回の発明を一層拡張、改良させたものに相当
する。The present invention corresponds to a further expansion and improvement of the previous invention.
前記したように、本発明者は褐藻類のカリウム結合体の
いわゆるアクティブ ファイバーカ特殊な生理効果を有
することに着目し、カリウム以外の必須生理的金属であ
るカルシウム、マグネシウム及び鉄を結合させたアクテ
ィブ ファイバーが一般的の消化管からの吸収促進ある
いはある種の吸収障害の場合のこれらミネラル類の補給
に有効であることを期待し、実験を行ない、この有効性
を実証し得た。As mentioned above, the present inventor focused on the fact that the so-called active fibers of brown algae that bind potassium have special physiological effects, and created active fibers that combine essential physiological metals other than potassium, such as calcium, magnesium, and iron. We expected that fiber would be effective in promoting general absorption from the gastrointestinal tract or in replenishing these minerals in cases of certain types of absorption disorders, and we conducted experiments and were able to demonstrate this effectiveness.
実施例１ニアクチイブ ファイバー・カルシウム（ＡＦ
Ｃａと略記する）の製造
褐藻、例えばアスコフィルム・ノドサム（Ａｓｃｏ −
７ｈ ｌｕｍ ｎｏｄｏｓｕｍ ）を粉砕したもの１０
０ｋｑに稀塩酸４００ｋを加えて攪拌し、濾過して塩酸
を除き、水２００Ｊで３回洗浄する。これに水酸化カル
シウム１ＣＪｋＱを水２００１に懸濁したものを徐々に
加えて攪拌し、ｐＨを６〜７に調整して濾過し、沈澱を
集めて６０°Ｃで乾燥する。Example 1 Niactive Fiber Calcium (AF
Production of brown algae, such as Ascophyllum nodosum (abbreviated as Ca)
7h lum nodosum) crushed 10
Add 400k of dilute hydrochloric acid to 0kq, stir, filter to remove hydrochloric acid, and wash 3 times with 200J of water. A suspension of 1CJkQ of calcium hydroxide in 2001 of water is gradually added and stirred, the pH is adjusted to 6-7, the mixture is filtered, and the precipitate is collected and dried at 60°C.
かくして得られたものは褐色の粉末で水にほとんど溶け
ず、わずかに海藻用の味及び臭を有する。イオン交換可
能なカルシウムの含量は約５％。The product thus obtained is a brown powder that is almost insoluble in water and has a slightly seaweed-like taste and odor. The content of ion-exchangeable calcium is approximately 5%.
本品はナトリウム イオンを含む溶液中において容易に
ナトリウム イオンを吸着シ、カルシウムイオンを放出
する性質を有する。This product has the property of easily adsorbing sodium ions and releasing calcium ions in solutions containing sodium ions.
実施例２ニアクチイブ ファイバー・マグネシウム（Ａ
ＦＭ９と略記する）の製造
こんぶの粉砕したもの１００／（９をとり、稀塩酸４０
０ｋを加えて攪拌し、濾過して塩酸を除き、水２００１
で５回洗浄し、炭酸マグネシウム１２ｋｑを水２００ｅ
に懸濁したものを徐々に加えて攪拌し、そのｐＨを６〜
７に調整する。このものを濾過して沈澱を集め、６０°
Ｃで乾燥する。Example 2 Niactive fiber magnesium (A
Production of crushed kelp (abbreviated as FM9) 100/(take 9, add 40% dilute hydrochloric acid)
Add 0k, stir, filter to remove hydrochloric acid, and water 2001
Wash 5 times with 12 kq of magnesium carbonate and 200 e of water.
Gradually add the suspension and stir to adjust the pH to 6~
Adjust to 7. Filter this, collect the precipitate, and
Dry at C.
かくして得られたものは黒色の粉末で僅かに海藻用の味
と臭味を有し、イオン交換可能なマグネシウム約３％を
含有する。本品はナトリウム イオンを含む溶液中で容
易にナトリウム イオンを吸着しマグネシウム イオン
を放出する性質を有する。The product thus obtained is a black powder with a slight seaweed taste and odor and contains about 3% of ion-exchangeable magnesium. This product has the property of easily adsorbing sodium ions and releasing magnesium ions in solutions containing sodium ions.
実施例３ニアクチイブ ファイバー・鉄（ＡＦ Ｆ／と
略記する）の製造
わかめの粉砕したもの１，００／ｃｑをとり、稀塩酸４
００１を加えて攪拌し、濾過して塩酸を除き、水２００
２で３回洗浄し、硫酸第一鉄４０ｋＱを水２００７Ｉに
懸濁したものを徐々に加えて攪拌し、そのｐＩ（を６〜
７に調整する。このものを濾過して沈澱を集め、６０°
Ｃで乾燥する。Example 3 Production of Niactive Fiber Iron (abbreviated as AF F/) 1,00/cq of ground seaweed was taken and diluted with dilute hydrochloric acid 4
Add 001 and stir, filter to remove hydrochloric acid, and add 200
2, and gradually added 40 kQ of ferrous sulfate suspended in 2007 I of water and stirred, until the pI (pI) was 6 to 6.
Adjust to 7. Filter this, collect the precipitate, and
Dry at C.
かくして得られたものは黒色の粉末で僅かに海藻様の味
と臭味を有し、イオン交換可能な鉄を約１４係含有する
。本品はナトリウムを含む溶液中で容易にナトリウム
イオンを吸着し、第一鉄イオンを放出する。The product thus obtained is a black powder with a slightly seaweed-like taste and odor, and contains about 14 parts of ion-exchangeable iron. This product easily dissolves sodium in solutions containing sodium.
Adsorbs ions and releases ferrous ions.
本発明品の生理的活性は下記の動物実験で示される：
実験方法
飼料中にＡＦＣａ％ＡＦＭ、又はＡＦＦｔをそれぞれ１
０チ混入し、高血圧（ＳＨＩｔ）ラット６１０匹からな
るＡＦＣａ群、ＡＦＭｑ群およびＡＦＦｔ群をそれぞれ
飼育した。又、ＳＨＲラッ）１０匹からなるコントロー
ル群は無添加飼料で飼育した。実験開始後の所定の日に
血圧及び体重測定を行なった。又、実験開始後１００日
目には各群のラットを採尿ゲージに移して採尿し、尿中
のカルシウムおヨヒマグネシウムを定量した。さらに、
ＡＦＦｅ飼育群のラットは実験終了後に採血し、その鉄
含量を定量した。The physiological activity of the product of the present invention is shown in the following animal experiments: Experimental method: Adding 1 1% each of AFCa%AFM or AFFt to the feed.
The AFCa group, the AFMq group, and the AFFt group, each consisting of 610 hypertensive (SHIt) rats, were bred. A control group consisting of 10 SHR rats was fed with additive-free feed. Blood pressure and body weight were measured on a predetermined day after the start of the experiment. Furthermore, on the 100th day after the start of the experiment, the rats in each group were transferred to a urine collection gauge to collect urine, and the calcium and magnesium content in the urine was determined. moreover,
Blood was collected from rats in the AFFe-fed group after the end of the experiment, and the iron content was quantified.
これらの結果は添付図面の第１図および第２図と下山の
表に示される通シであって、血圧の上昇を防ぎ、体重の
増加を来たす点において、いずれの飼育群もコントロー
ル群に比して顕著な差を認めだ。These results are consistent with those shown in Figures 1 and 2 of the attached drawings and Shimoyama's table, and all rearing groups were superior to the control group in terms of preventing increases in blood pressure and increasing body weight. I found a noticeable difference.
表
本発明のＡＦ Ｃａ 、 ＡＦＭｑおよびＡＦＦｚ （
７）各０．２２を１錠中に各含有するように調製した錠
剤各２０錠ずつをボランティア−１ｏ名に１日６回ずつ
２週間服用させたが、みるべき副作用は１例も認められ
なかった。Table AF Ca, AFMq and AFFz (
7) 10 volunteers were given 20 tablets each containing 0.22% of each drug 6 times a day for 2 weeks, but no notable side effects were observed. There wasn't.
かくして、本発明のＡＦＣａ、ＡＦＭｐおよびＡＦＦｅ
は他飼料と共に人間又は動物に投与することにより、そ
れぞれナトリウム・イオンは吸着されて消化管からの吸
収を抑制してす） ＩＪウム イオンの過剰摂取による
高血圧症や脳卒中を予防する効果が期待されると共に放
出されたカルシウム又はマグネシウムは溶液として容易
に消化管から吸収され、又、第一鉄イオンも２価の鉄イ
オンとして容易に消化管から吸収され、それぞれのイオ
ンを生体に補給して効果をもたらす役割を果たすと考え
られる。Thus, AFCa, AFMp and AFFe of the present invention
When administered to humans or animals along with other feeds, sodium ions are adsorbed and inhibit absorption from the gastrointestinal tract.) It is expected to be effective in preventing hypertension and stroke caused by excessive intake of IJium ions. Calcium or magnesium released as a solution is easily absorbed from the gastrointestinal tract as a solution, and ferrous ions are also easily absorbed from the gastrointestinal tract as divalent iron ions, and each ion is replenished to the body and has an effect. It is believed that this plays a role in bringing about this.
製剤例
本発明品の製剤例を次に例示するニ
アクチイブ ファイバー・カルシウム錠；ＡＦＣａ
２００？結晶セルロース
５ Ｑ ｔｔ乳糖 ２０ノ／
でんぷん １５〃デキストリ
ン １０１／シユガーエステル
５１計
３０Ｃ１各成分を常法により１錠３００ｑの錠剤にす
る。Formulation Example The following formulation example of the product of the present invention is Niactiv Fiber Calcium Tablet; AFCa
200? crystalline cellulose
5 Q tt Lactose 20 / Starch 15 Dextrin 101 / Shugar ester
51 total
Each component of 30C1 is made into a 300q tablet by a conventional method.
アクティブ ファイバー・マグネシウム錠；ＡＦＭｑ２
０ Ｏｒ
結晶セルロース ５０〃乳糖
２０７１
でんぷん １５１１デキストリ
ン １０１１シユガーエステル
５ ｔｔ計
５００２各成分を常法により１錠３００岬の錠剤
にする。Active fiber magnesium tablet; AFMq2
0 Or crystalline cellulose 50 Lactose
2071 Starch 1511 Dextrin 1011 Sugar ester
5 tt meter
5002 Each ingredient is made into 300 tablets by a conventional method.
アクティブ ファイバー・鉄腕；
ＡＦＦ＃ ２００ ？結晶セ
ルロース ５０〃乳糖 ２
０〃
でんぷん １５／／デキスト
リン １０〃シユガーエステル
５１計
３０Ｏｆ各成分を常法によ９１錠３００ダの錠剤にす
る。Active fiber iron arm; AFF# 200? Crystalline cellulose 50 Lactose 2
0 Starch 15 // Dextrin 10 Shugar ester
51 total
30Of each ingredient is made into 91 tablets of 300 Da each by a conventional method.
本錠剤はそのまま服用するか、あるいは他の食品に添加
、配合して摂取することに利用される。This tablet can be taken as is, or added to or mixed with other foods.
第１図は本発明名品を１０チ混入した飼料により高血圧
ラットを飼育した場合の血圧の対照との比較における高
下を示す線図。第２図は同上体重の増減を示す線図。
−ｏ−ｔｒｉ ＝ｒノントロール群−か−ハＡ Ｆ Ｍ
ｆ 摂取群、−に−はＡＦＣａ摂取群摂取−はＡＦＦ＃
摂取群の成績を各々示す。
（特許出願人 清水化学株式会社）
（代理人 弁理士 糟谷 安）FIG. 1 is a diagram showing the increase and decrease in blood pressure in comparison with a control when hypertensive rats are fed with feed containing 10 grams of the famous product of the present invention. Figure 2 is a diagram showing the increase and decrease in body weight as above. -o-tri =r non-troll group-ka-ha A F M
f intake group, - to - is AFCa intake group intake - is AFF#
The results of each intake group are shown. (Patent applicant: Shimizu Chemical Co., Ltd.) (Representative: Patent attorney Yasu Kasuya)
Claims (1)
シウム、マグネシウムおよび鉄よりなる群より選ばれた
金属を水溶液中で結合させｐＨ６〜７に調整して脱水し
固体とした経口用組成物。 ２、酸を用いて可及的に脱金属処理をした褐藻類にカル
シウム、マグネシウムおよび鉄よりなる群より選ばれた
金属を水溶液中で結合させｐＨ６〜７に調整して脱水し
固体とした組成物を３０重量％以上含有させたことを特
徴とする経口用錠剤。[Claims] 1. A metal selected from the group consisting of calcium, magnesium and iron is bound to brown algae which has been subjected to a metal removal treatment as much as possible using an acid in an aqueous solution and the pH is adjusted to 6 to 7. A dehydrated solid oral composition. 2. A composition in which a metal selected from the group consisting of calcium, magnesium, and iron is bound to brown algae that has been demetallized as much as possible using an acid, and the pH is adjusted to 6 to 7 and dehydrated to form a solid. An oral tablet characterized by containing 30% by weight or more of a substance.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61021055A JPS62178520A (en) | 1986-01-31 | 1986-01-31 | Metal-bonded active fibrous material containing marine algae |
| US06/869,906 US4804536A (en) | 1985-06-13 | 1986-06-03 | Dietary fibres of seaweed having ion-exchange ability |
| CA000511061A CA1281588C (en) | 1985-06-13 | 1986-06-06 | Dietary fibres of seaweed having ion-exchange ability |
| EP86108008A EP0205174A3 (en) | 1985-06-13 | 1986-06-12 | Dietary food of seaweed having ion-exchange capability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61021055A JPS62178520A (en) | 1986-01-31 | 1986-01-31 | Metal-bonded active fibrous material containing marine algae |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62178520A true JPS62178520A (en) | 1987-08-05 |
| JPH0362703B2 JPH0362703B2 (en) | 1991-09-26 |
Family
ID=12044224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61021055A Granted JPS62178520A (en) | 1985-06-13 | 1986-01-31 | Metal-bonded active fibrous material containing marine algae |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62178520A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60160865A (en) * | 1984-01-31 | 1985-08-22 | Shimizu Kagaku Kk | Production of food having salt reducing action |
-
1986
- 1986-01-31 JP JP61021055A patent/JPS62178520A/en active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60160865A (en) * | 1984-01-31 | 1985-08-22 | Shimizu Kagaku Kk | Production of food having salt reducing action |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0362703B2 (en) | 1991-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1139673A (en) | Spherical particles of activated carbon suitable for use as an antidotal pharmaceutical composition | |
| US4822765A (en) | Process for treating activated carbon with aqueous ammonia | |
| US4814354A (en) | Lipid regulating agents | |
| CA1112172A (en) | Antidote consisting of particles of activated carbon | |
| FI98193C (en) | Method for the preparation of a magnesium additive for food, feed and medicines | |
| KR20130095268A (en) | Adsorbent for oral administration, method for producing same, and drug using same | |
| JP2001527022A5 (en) | ||
| JPS62178520A (en) | Metal-bonded active fibrous material containing marine algae | |
| US20060233894A1 (en) | Anti-Inflammatory Humate Compositions and Methods of Use Thereof | |
| US7662364B2 (en) | Drug for hyperphospheremia and its preparative method | |
| US4804536A (en) | Dietary fibres of seaweed having ion-exchange ability | |
| JPS6154389B2 (en) | ||
| US9585913B2 (en) | Clay mineral for reducing inorganic phosphates, in particular in renal replacement therapy | |
| JPH02188415A (en) | Natural hydroxyapatite, or the like and production thereof | |
| JP2003327537A (en) | Oral medicine for treating malignant tumor | |
| CN112891369A (en) | Potassium chloride sustained-release tablet prepared by taking crab shell powder and derivative product thereof as auxiliary materials and preparation method | |
| WO2021100837A1 (en) | Composition for preventing or reducing hyperuricemia, and method for producing same | |
| JP4435427B2 (en) | Formulation for bowel function adjustment | |
| CN100411631C (en) | Orally administered compound antihyperlipidemic | |
| WO2017081079A1 (en) | Combination of calcium sulfate and gum arabic | |
| CN1199611A (en) | Calcium replenishing chewing tablet | |
| EP0136502A2 (en) | Use of ferro, zinc and magnesium salts and their mixed salts for the substitution of iron, zinc and magnesium | |
| Tone et al. | Effect of ingested gossypol on the growth performance of rats | |
| JPS61285967A (en) | Edible algal composition having improved ion exchange capability and utilization thereof as food | |
| US4774258A (en) | Treatment of urinary calculi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |